Skip to main content

RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities

Objective

RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mortality and morbidity, both from uncontrolled disease and treatment associated co-morbidities, like infection and malignancy. This requires the need to stratify patients by their outcome and to tailor immunosuppression based on much deeper knowledge of the mechanisms that control initiation and persistence of the pathogenic immune responses. The RELENT Consortium has been formed to generate this knowledge with the ultimate goal of developing treatments tailored to the specific needs of individual patients. RELENT combines the resources of seven leading European Investigators and two from US and Australia whose expertise is not available elsewhere in the world but necessary for the ambitious work program. Three SMEs will supply specific reagents and translate the results to biomarker development. This will enable RELENT to deliver its four specific research aims, namely to: i) Combine subset analysis of genome wide association studies with classical cell biology to uncover pathways that influence and ii) use multiplexed antigen arrays, whole proteome analysis and rapid mass analysis to identify protein signatures that predict outcome and response to treatment in chronic autoimmune disease. iii) Characterise T and B cell abnormalities that predispose to autoimmunity and infection by studying the ageing immune system in health and disease. iv) Analyse pathogenic effector T cells and their control by macrophages and dendritic cells and the molecules they secrete using in vivo models. We anticipate to identify common mechanisms responsible for the persistence and outcomes in severe autoimmune and inflammatory diseases in females and males and that the results should be rapidly translatable into clinical practice for the benefit of patients.

Field of science

  • /natural sciences/biological sciences/cell biology
  • /medical and health sciences/health sciences/inflammatory diseases
  • /medical and health sciences/basic medicine/immunology

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

MEDIZINISCHE UNIVERSITAET WIEN
Address
Spitalgasse 23
1090 Wien
Austria
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 133 200,75

Participants (14)

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 530 390
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 524 500
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany
EU contribution
€ 494 237,50
Address
Ingolstadter Landstrasse 1
85764 Neuherberg
Activity type
Research Organisations
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 456 242,50
Address
Venusberg-campus 1
53127 Bonn
Activity type
Higher or Secondary Education Establishments
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 395 635
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
KUNGLIGA TEKNISKA HOEGSKOLAN
Sweden
EU contribution
€ 461 250
Address
Brinellvagen 8
100 44 Stockholm
Activity type
Higher or Secondary Education Establishments
Mayo Clinic

Participation ended

United States
EU contribution
€ 0
Address
First Street Sw 200
55905 Rochester
Activity type
Research Organisations
MONASH UNIVERSITY
Australia
EU contribution
€ 0
Address
Wellington Road
3800 Victoria
Activity type
Higher or Secondary Education Establishments
EMC MICROCOLLECTIONS GMBH
Germany
EU contribution
€ 471 250
Address
Sindelfinger Str. 3
72070 Tuebingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Hycult biotechnology bv
Netherlands
EU contribution
€ 449 937,50
Address
Frontstraat 2A
5405 PB Uden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PHENOCELL
France
EU contribution
€ 443 500
Address
45 Boulevard Marcel Pagnol
06130 Grasse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Participation ended

Germany
EU contribution
€ 38 576
Address
Oskar Von Miller Ring 29
80333 Muenchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ARTTIC
France
EU contribution
€ 211 532
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 389 180
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments